© 2020 MJH Life Sciences and Neurology Live. All rights reserved.
© 2020 MJH Life Sciences™ and Neurology Live. All rights reserved.
September 22, 2020
A study presented at MS Virtual reveals that treatment with ocrelizumab can improve freedom of individual events in patients with relapsing-remitting multiple sclerosis.
September 21, 2020
Future research may help better characterize whether fatigue interventions aimed at one patient population may be effective in the other.
In honor of World Alzheimer’s Day, NeurologyLive is sharing some of the latest clinical developments and thoughts from leaders in the field.
September 18, 2020
Along with being generally well tolerated, ozanimod was able to help most patients become relapse free without disability progression.